看了招股书，维立志博_老虎社区_美港股上老虎

看了招股书，维立志博14 款候选药中6款已经进入临床，全球进度第二的GPRC5D/CD3双抗 LBL-034、全球仅有的两款MUC16/CD3双抗之一LBL-033，还有核心产品LBL-024，这些爆款潜质可以押注一下

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":450108799775216,"tweetId":"450108799775216","gmtCreate":1750916726016,"gmtModify":1750917959769,"author":{"id":4090740760034840,"idStr":"4090740760034840","authorId":4090740760034840,"authorIdStr":"4090740760034840","name":"数字74581","avatar":"https://static.tigerbbs.com/de5d817a32bf8023884cb12b8b17d208","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>看了招股书，维立志博14 款候选药中6款已经进入临床，全球进度第二的GPRC5D/CD3双抗 LBL-034、全球仅有的两款MUC16/CD3双抗之一LBL-033，还有核心产品LBL-024，这些爆款潜质可以押注一下</body></html>","htmlText":"<html><head></head><body>看了招股书，维立志博14 款候选药中6款已经进入临床，全球进度第二的GPRC5D/CD3双抗 LBL-034、全球仅有的两款MUC16/CD3双抗之一LBL-033，还有核心产品LBL-024，这些爆款潜质可以押注一下</body></html>","text":"看了招股书，维立志博14 款候选药中6款已经进入临床，全球进度第二的GPRC5D/CD3双抗 LBL-034、全球仅有的两款MUC16/CD3双抗之一LBL-033，还有核心产品LBL-024，这些爆款潜质可以押注一下","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/450108799775216","repostId":0,"isVote":1,"tweetType":1,"viewCount":392,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":166,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}